蝙蝠葛碱和粉防己碱对[~3H]WEB 2086与体外牛脑前动脉平滑肌细胞结合的影响(英文)

用标记的血小板活化因子拮抗剂[~3H]WEB 2086,在培养的牛脑前动脉平滑肌细胞上鉴定了血小板活化因子受体。结果表明在25℃时该细胞上存在两种与配基具有不同亲和力的受体结合位点,其中K_(d-1)=22.8±5.0 nmol·L~(-1),K_(d-2)=186+20.5 nmol·L~(-1);B_(max-1)=2.1±0.3 pmol/10~4细胞,B_(max-2)=12.1±1-5 pmol/10~6细胞。蝙蝠葛碱和粉防己碱均能抑制[~3H]WEB2086与上述细胞的结合。     

粉防己碱,小檗胺等四氢异喹啉类生物碱对大鼠脑内M-胆碱受体的作用

用放射受体结合方法,研究了36种四氢异喹啉类生物碱及其半合成衍生物对大鼠脑内M-胆碱受体的结合特性。实验发现,粉防己碱对M-胆碱受体的亲和力最高,其K_i值为7.3×10^-8mol/L。小檗胺、四氢黄连碱和半合成原小檗碱衍生物B₁亦具有较高亲和力,K_i值分别为1.9×10^-7,6.8×10^-7和8.1×10^-7mol/L。四氢小檗碱半合成原小檗碱衍生物B₂,B₃,B₄,B₅,B₆和半合成小檗胺衍生物E₁及半合成蝙蝠葛碱衍生物D₁对M-胆碱受体的亲和力为中等强度,K_i值在1～2×10^-6mol/L之间。实验结果提示,某些四氢异喹啉类生物碱的药理作用可能与M-胆碱受体有关。     

毒毛旋花子苷元对豚鼠心室肌细胞内钙浓度的影响

观察毒毛旋花子苷元(strophanthidin, Str)对分离豚鼠心室肌细胞内游离钙浓度(［Ca²⁺］_i)的影响。酶解分离豚鼠心室肌细胞, 用Fluo 3-AM负载, 激光共聚焦显微镜法测定单个豚鼠心室肌细胞［Ca²⁺］_i的荧光密度。Str可浓度依赖性地升高［Ca²⁺］_i, Str (10 μmol·L^-1)在［Ca²⁺］_i升高达峰值时, 可使细胞挛缩, 而Str (1和10 nmol·L^-1)对细胞形态无影响。TTX、 尼索地平或升高细胞外钙可影响Str (1和100 nmol·L^-1)对［Ca²⁺］_i的升高作用,而对Str (10 μmol·L^-1)无明显影响。在外液中加入ryanodine或去除细胞外钙, 则3个检测浓度的Str升高［Ca²⁺］_i作用均被明显抑制。在无K⁺、 无Na⁺液中, 10 μmol·L^-1 Str升高［Ca²⁺］_i的作用减弱, 而Str (1和100 nmol·L^-1)升高［Ca²⁺］_i的作用无明显影响。加入TTX、 尼索地平或增加细胞外的钙离子浓度, 则3个检测浓度Str的作用均受到影响。提示低浓度Str对［Ca²⁺］_i的升高作用与抑制Na⁺、K⁺-ATP酶活性无关, 而与促进L-型钙通道和TTX敏感性钠通道的“slip-mode”钙电导有关; 高浓度Str升高［Ca²⁺］_i的作用则是抑制Na⁺、K⁺-ATP酶的结果。此外, Str对［Ca²⁺］_i的升高作用还与直接作用于ryanodine受体促进内钙释放有关。     

新型α-黑素细胞刺激素类似物亲和力和生物学效应的测定

检测新型α-黑素细胞刺激素(α-MSH)类似物与受体的亲和力和生物学效应。构建黑皮质激素受体表达质粒，经测序鉴定后以磷酸钙-DNA共沉淀法转染HEK-293细胞，48 h后加入含900 μg·mL^-1 G418的细胞维持液，稳定表达后以流式细胞仪检测。采用放射性配体结合分析测定新型α-MSH类似物对受体的亲和力，并以［³H］环磷酸腺苷(cAMP)测定盒检测新型α-MSH类似物作用细胞后的cAMP水平。结果显示，新型α-MSH类似物对MC1R，MC3R，MC4R及MC5R的抑制常数K_i分别为(0.159±0.040)，(35.430±6.743)，(19.293±2.780)和(2.230±0.670) nmol·L^-1。其对MC1R，MC3R，MC4R及MC5R的EC₅₀值分别为(0.45±0.07)，(7.80±0.65)，(2.55±0.23)和(0.33±0.09) nmol·L^-1。新型α-MSH类似物是MC1R和MC5R高选择性的激动剂。     

安定在家兔体内的肠胃循环药代动力学分析

6只家兔iv安定5 mg·kg^-1后,浓度—时间数据呈现双峰形。本文提出肠胃循环动力学模型,用于分析实测数据,得到了一般动力学参数:T_1/2(α)=0.21±=0.15 h,T_1/2(β)=2.2+0.6 h,K_e=1.5±0.6 h^-1,K₁₂=2.0±1.0 h^-1,K₂₁=1.0±0.4 h^-1,V₁=3.1±1.6 L·kg^-1,AUC=1.7±0.5μg·h^-1·ml^-1。此外,还求得有关肠胃循环的参数,即:重吸收滞后时间T′=0.25±0.24h,重吸收速率常数K_A=3.5±1.4 h^-1,重吸收率R_A=24±7%。     

可变误差多面体法用于多种维生素的同时测定

本文基于对多元校正分析模型的简要讨论,探索了应用可变误差多面体法同时测定维生索B₁,B₂,B₆和烟酰胺的可行性。其结果准确度和精密度均较满意。维生素B₁,B₂,B₆及烟酰胺的回收率分别是99.8±0.9%(CV),100.1±0.8%(CV),100.2±2.1%,100.1±0.7%(CV)。结果表明,通过公式K_S=A_SC_S^T(C_SC_S^T)^-1计算校正系数矩阵K_S,并结合可变误差多面体法这一直接求解方法,能有效地提高分析结果的准确度,克服组分间的交互作用及病态,是多元校正分析的较佳策略之一。     

赛庚啶对大鼠心肌细胞膜[3H]-d-cis-硫氮卓酮结合部位的影响

苯并噻嗪类钙通道阻滞剂[³H]-d-cis-硫氮酮能以一种特异和可饱和的方式与离体大鼠心肌细胞膜结合,其K_D值和B_max分别为84nmol·L^-1和0.279pmol·mgprotein^-1。非标记的硫氮酮和赛庚啶均能完全抑制这种结合,其Ki值分别为102nmolL^-1和5.5umol·L^-1。上述结果证实在大鼠心肌细胞膜上也存有[³H]-硫氮酮受体,同时还提示赛马庚啶对心肌细胞膜的钙通道阻滞作用可能与作用于心肌细胞膜[³H]硫氮酮受体有关。     

银杏叶提取物对低氧复氧、H2O2和谷氨酸损伤时谷氨酸引起的大鼠星形胶质细胞［Ca2+］i变化的影响

目的研究银杏叶提取物对低氧复氧、H₂O₂和L-谷氨酸损伤时谷氨酸升高大鼠星形胶质细胞［Ca²⁺］_i的影响。方法钙荧光探针Fluo-3/AM标记胞浆内游离钙离子，激光扫描共聚焦显微镜测定［Ca²⁺］_i的变化。结果 在低氧复氧、H₂O₂以及高浓度的L-谷氨酸损伤后，外源性谷氨酸（27 μmol·L^-1）均不能引起培养乳大鼠星形胶质细胞正常的［Ca²⁺］_i升高，反而使［Ca²⁺］_i分别降低(3.3±1.6)%，(81±11)%和(81±7)%；损伤前预先给予GbE（10 mg·L^-1）不能明显改善星形胶质细胞的谷氨酸反应，但预先给予GbE（100 mg·L^-1）后，27 μmol·L^-1谷氨酸可使损伤的星形胶质细胞［Ca²⁺］_i分别升高(135±98)%，(117±93)%和(89±36)%。结论低氧复氧、H₂O₂以及高浓度的L-谷氨酸均能损伤星形胶质细胞的谷氨酸反应，影响神经细胞与胶质细胞的双向交流。GbE能明显逆转不同损伤后谷氨酸诱导星形胶质细胞［Ca²⁺］_i的异常变化，使星形胶质细胞在不同损伤时能维持正常功能，该作用可能与GbE的脑保护作用有关。     

槐果碱对HERG钾通道电生理功能的影响

HERG(human ether-a-go-go-related gene)钾通道在心律失常的发生及治疗中具有重要作用， 因此已成为近些年来的研究热点。本研究应用全细胞膜片钳技术记录在HEK(human embryonic kidney) 293细胞上稳定表达的HERG钾通道的电流和动力学曲线(激活、 失活、 复活和去活化)来研究不同浓度槐果碱对HERG电流及动力学曲线的影响， 以了解槐果碱抗心律失常的作用机制。结果表明， 槐果碱浓度依赖性地抑制HERG时间依赖性电流(I_step)及其尾电流(I_tail)。在0 mV时， 10、 30、 100及300 μmol·L^-1槐果碱对I_step的抑制率分别为(10.7±2.8)%、 (11.3±5.5)%、 (47.0±2.3)%及(53.7±2.5)%， 对I_tail的抑制率分别为(1.1±3.0)%、 (17.1±3.3)%、 (32.7±1.9)%(P<0.05， n=12)及(56.0±2.4)%(P<0.05， n=13)。100 μmol·L^-1槐果碱作用后失活时间常数减小， 失活速率变快；复活时间常数在大部分指令电压下明显减小(P<0.01， n=12)，复活速度加快；瞬时失活时间常数减小(P<0.05， n=12)；稳态激活、去活化无明显改变。由此可看出，槐果碱通过影响通道的失活过程抑制HERG钾电流，使得心肌细胞复极时间延长，改善快速性心律失常。     

慢性孵育β-淀粉样肽(25-35)对培养大鼠海马神经元外向钾电流的影响

目的　研究慢性孵育β-淀粉样肽_(25-35) (β-AP_25-35)对海马神经元上瞬时外向钾电流(I_A)和延迟整流钾电流(I_K)的影响。方法　在培养的大鼠海马神经元上用膜片钳全细胞记录钾通道电流。结果　β-AP_25-35 3μmol·L^-1 孵育细胞24h ,I_K 电流幅度增加(44.3±5.4)% ,电流密度由(30.4±6.4)pA·PF^-1 增加至(43.8±4.7)pA·PF^-1 ;β-AP_25-3510μmol·L^-1 孵育12h ,I_K 电流幅度增加(69.8±4.1) % ,电流密度增加至(51.6±7.9)pA·PF^-1,呈浓度依赖性;β-AP_25-35引起的I_K 增加对TEA 5mmol·L^-1 敏感;β-AP_25-35上调I_K 的作用主要发生在β-AP_25-355用药后48h内。β-AP_25-35对I_A无显著性影响。结论　β-AP_25-35选择性地增加海马神经元上I_K,这一作用可能与β-AP的神经毒性有关     

COMPARATIVE STUDY ON α1-ADRENOCEPTOR ANTAGONIST BINDING IN HUMAN PROSTATE AND AORTA

1. Specific binding of [³H]-prazosin in prostatic and aortic membranes of humans was saturable and of high affinity (prostate: apparent dissociation constant, K_d= 0.35 ± 0.03 nmol/L; aorta: K_d= 0.26 ± 0.03 nmol/L). The density of [³H]-prazosin binding sites (B_max) for prostate and aorta was 546 ± 31 and 61.6 ± 1.6 fmol/mg protein, respectively. 2. Prazosin, YM617, naftopidil and urapidil competed with [³H]-prazosin for the binding sites in a dose-dependent manner in the prostate and aorta of humans. The binding affinities of these antagonists in both tissues were compared, based on the inhibition constant, K_i. Both prazosin and urapidil showed similar affinity to [³H]-prazosin binding sites in human tissue, whereas YM617 and naftopidil showed approximately a 12 and two times higher affinity, respectively, to α₁-adrenoceptor sites of prostate than aorta. 3. The chloroethylclonidine treatment reduced partially the B_max values for specific [³H]-prazosin binding in the prostate and aorta of humans with little effect on the K_d values. 4. These data suggest that YM617 is a relatively selective antagonist of human prostatic α₁-adrenoceptors.     

Characterization of the [3H]-desipramine binding site of the bovine adrenomedullary plasma membrane

Summary The specific (i.e. nisoxetine-sensitive) binding of [³H]desipramine was studied in membranes prepared from bovine adrenal medullae. (1) [³H]desipramine bound reversibly and with high affinity (K _D = 2.8 nmol/l) to a single class of non-interacting binding sites (Hill coefficient = 0.96); the maximal number of binding sites (B_max) was 2.1 pmol/mg protein. (2) Binding of [³H]desipramine was dependent on [Na⁺] and [Cl^–]. Increasing the concentrations of these ions increased binding. (3) Substrates and inhibitors of the neuronal noradrenaline transport system (uptake,) inhibited binding of [³H]desipramine with a rank order of potency typical for an interaction with the uptake, carrier.The characteristics of [³H]desipramine binding remained essentially unchanged after solubilization of adrenomedullary membranes with the non-ionic detergent digitonin.The results indicate that the plasma membrane of bovine adreno-medulary cells is endowed with the neuronal uptake₁ transporter. Correspondence to: H. Bönisch     

CHARACTERIZATION OF BINDING SITES FOR [3H]-IDAZOXAN, [3H]-P-AMINOCLONIDINE AND [3H]-RAUWOLSCINE IN THE KIDNEY OF THE DOG

1. We characterized the binding of [³H]-rauwolscine, [³H]-p-aminoclonidine and [³H]-idazoxan in a dog kidney membrane preparation. Our aim was to determine the pharmacological nature of the α₂-adrenoceptor- and imidazoline-preferring binding sites in this organ. 2. [³H]-Rauwolscine bound to an apparent single site with an affinity (K_D) of 2.2 nmol/ L and a maximum density (B_max) of 58.5 fmol/mg protein, when 10 μmol/L idazoxan defined non-specific binding. However displacement studies demonstrated that a number of compounds, including prazosin, inhibited [³H]-rauwolscine binding in a complex manner consistent with displacement from two distinct binding sites. The majority (69%) of the [³H]-rauwolscine binding sites had a relatively low affinity for prazosin (K_I= 398 nmol/L), while the remainder had a relatively high affinity for prazosin (K_I= 7.9 nmol/ L). 3. [³H]-p-Aminoclonidine bound to an apparent single site (K_D= 5.2 nmol/L; B_max= 72.4 fmol/mg protein), when 10 μmol/L phentolamine defined non-specific binding. When 1 μmol/L of the potent and selective α₂-adrenoceptor antagonist 2-methoxyidazoxan was included in the incubate, no specific binding was detected. We therefore conclude that under the conditions of this experiment [³H]-p-aminoclonidine binds only to α₂-adrenoceptors in the dog kidney. 4. [³H]-Idazoxan bound to two sites, with a higher (K_D= 0.95 nmol/L; B_max= 43.9 fmol/mg protein) and lower (K_D= 9.1 nmol/L; B_max= 93.8 fmol/mg protein) affinity, respectively, when 1 mmol/L phentolamine defined non-specific binding. When 10 μmol/ L GTPγS was included in the incubate, the low affinity site was unaffected but the maximum binding at the higher affinity site was reduced by 79%. 2-Methoxyidazoxan displaced [³H]-idazoxan in a monophasic manner and with low potency (IG₅₀=11.5 μmol/L). Yohimbine, efaroxan, clonidine, rilmenidine, guanabenz and idazoxan itself displaced [³H]-idazoxan in a complex manner; the slope of the displacement curves being less than unity. 5. We conclude that the dog kidney contains a heterogeneous population of α₂-adrenoceptors that can be labelled either with [³H]-rauwolscine or [³H]-p-aminoclonidine. The dog kidney also contains a heterogeneous population of non-adrenoceptor imidazoline-preferring binding sites of the I₂-subtype, that can be labelled with [³H]-idazoxan. The binding site for which [³H]-idazoxan has the highest affinity appears to be coupled to a guanine nucleotide binding regulatory protein.     

3H]WEB 2086 labels platelet activating factor receptors in guinea pig and human lung

The radiolabelled platelet activating factor (PAF) receptor antagonist, [3H]WEB 2086, bound to specific sites on membrane fractions from homogenised guinea pig and human lungs. The sites on guinea pig and human membranes bound [3H]WEB 2086 with dissociation constants (KD) of 16.8 and 22.6 nM and binding capacities (Bmax) of 203 and 157 fmol/mg protein, respectively. In both species, binding was displaced competitively by PAF, suggesting that the sites labelled by [3H]WEB 2086 are PAF receptors.     

[3H]2-(2-Benzofuranyl)-2-imidazoline,a highly selective radioligand for I2-imidazoline receptor binding sites Studies in rabbit kidney membranes

2-(2-Benzofuranyl)-2-imidazoline (2-BFI) has recently been characterised as a selective ligand for the I₂-type of imidazoline-receptor binding site(s) (I₂-RBS). The present studies determined the relative levels of specific [³H]2-BFI binding to membrane homogenates of brain and kidney from rat, guinea pig and rabbit and identified the pharmacological characteristics of [³H]2-BFI binding sites in rabbit kidney membranes. Rabbit kidney membranes had the highest relative density of specific [³H]2-BFI binding of all tissues studied (2000?fmol/mg protein). Rabbit brain and guinea pig kidney had moderate levels of specific [³H]2-BFI binding (350–500?fmol/mg protein), while rat kidney and guinea pig and rat brain displayed much lower densities of binding (40–65?fmol/mg protein). Studies of [³H]2-BFI binding kinetics in rabbit kidney homogenates revealed binding to two distinct sites with K _d values of 0.10?±?0.01?nmol/l and 1.00?±?0.36?nmol/l respectively. Equilibrium saturation studies were also consistent with the presence of two binding sites – [³H]2-BFI (0.01–20?nmol/l) bound to sites with affinities of 0.10?± 0.01?nmol/l and 0.92?±?0.13?nmol/l and binding densities of 470?±?80 and 840?±?60?fmol/mg protein (n=3), representing 36 and 64% respectively. Drug inhibition studies revealed that l-adrenaline; α₁-adrenoceptor drugs (prazosin, l-phenylephrine) and α₂-adrenoceptor drugs (rauwolscine, methoxyidazoxan, 2-(2,4-(O-methoxyphenyl)-piperazin-1-yl)-ethyl-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione (ARC-239) had extremely low affinities for [³H]2-BFI binding sites (IC₅₀?≥?10?μmol/l). Putative I₁-RBS compounds, p-aminoclonidine, moxonidine, imidazole-4-acetic acid and cimetidine, inhibited [³H]2-BFI binding to rabbit renal membranes with low to very low affinities (K _i values 3 to ≥100?μmol/l), suggesting [³H]2-BFI does not label I₁-RBS in rabbit kidney membranes. I₂-RBS compounds – 2-(4,5-dihydroimidaz-2-yl)-quinoline (BU224), 2-(4,5-dihydroimidaz-2-yl)-quinoxaline (BU239), idazoxan and cirazoline – potently inhibited [³H]2-BFI binding (K _i values 0.37–1.6?nmol/l), confirming the labelling of I₂-RBS. Inhibition of [³H]2-BFI binding by certain compounds was consistent with their interaction with two binding site populations – for example (drug, K _i values) guanabenz, 0.65?nmol/l and 0.17?μmol/l; naphazoline, 0.94?nmol/l and 2.8?μmol/l; amiloride, 76?nmol/l and 26?μmol/l rilmenidine, 150?nmol/l and 50?μmol/l; and clonidine, 230?nmol/l and 70?μmol/l. The high affinity of amiloride for a high proportion (85%) of the binding is consistent with the presence of the I_2A-subtype of I-RBS in rabbit kidney. These results demonstrate that [³H]2-BFI is a highly selective and high affinity radioligand for I₂-RBS which should be useful for the further characterisation of these sites in mammalian tissues.     

Autoradiographic study of peripheral benzodiazepine receptors in animal brain tumor models and human gliomas

In vitro binding of [³H]PK-11195 (1-(2-chlorophenyl)-N-methyl-(1-methylpropyl)-3-isoquinoline carboxamide) in rodent AA ascites and C6 glioma as well as in human gliomas was investigated. The B_max (mean ± S.D.) of AA ascites tumor and C6 glioma is 1.39 ± 0.15 pmol/mg tissue and 4.50 ± 0.76 pmol/mg tissue, respectively. This B_max is 9 and 30 times, respectively, higher than the one found in the rat cortex (0.15 ± 0.03 pmol/mg tissue). A B_max of 1.26 ± 0.24 pmol/mg tissue and 0.64 ± 0.08 pmol/mg tissue was found in human malignant and low grade gliomas respectively. This B_max value should be compared to 0.35 ± 0.04 pmol/mg tissue found in the normal human cortex. There are significant (P < 0.05) differences between B_max in tumors and normal cortex. There was no significant difference in K_D between the malignant and low grade gliomas. C6 glioma has a K_D significantly greater than rat cortex. In some cases of human low grade gliomas, kinetic measurements suggested the presence of two affinity receptor sites. However, at this time, heterogeneity of the tissue cannot be excluded as being at least in part a source of this.     

Platelet 5-HT uptake sites in depression: three concurrent measures using [3H] imipramine and [3H] paroxetine

Platelet 5-HT uptake sites were measured in 40 depressed patients and 40 controls using [³H] imipramine binding, defined with desmethylimipramine (DMI) and Na⁺ dependence, and [³H] paroxetine binding. In control subjects the B_max of DMI defined [³H] imipramine binding was significantly higher than both Na⁺ dependent [³H] imipramine (by 30%) and [³H] paroxetine binding (by 22%). The B_max of Na⁺ dependent [³H] imipramine and [³H] paroxetine binding did not differ significantly. The K_d of Na⁺ dependent [³H] imipramine binding was significantly lower than the K_d of DMI defined [³H] imipramine binding. The binding of DMI defined and Na⁺ dependent [³H] imipramine and [³H] paroxetine did not differ significantly between depressed patients and controls in the total group, in those depressed patients who had never taken antidepressants or in those depressed patients who had been recently with-drawn from antidepressants. This study provides no support for the view that the number of platelet 5-HT uptake sites are reduced in depression.     

Binding of3H-desipramine to the neuronal noradrenaline carrier of rat phaeochromocytoma cells (PC-12 cells)

Summary The specific (i.e., nisoxetine-sensitive) binding of³H-desipramine was studied in purified plasma membranes of PC-12 cells (rat phaeochromocytoma cells).³H-desipramine bound reversibly and with high affinity (K _D=4.5 nmol/l) to a single, non-interacting site (Hill coefficient=1.04); the maximal number of binding sites (B _max) was 19.6 pmol/mg protein.Like the uptake of noradrenaline (by uptake₁), the binding of³H-desipramine was dependent on both sodium and chloride. The stimulation of binding by chloride and sodium was characterized by a Hill coefficient of about 1 and 2, respectively. Both, chloride and sodium, slowed the rate of dissociation of bound³H-desipramine. Increasing concentrations of sodium decreased theK _D of³H-desipramine binding without altering theB _max.The binding of³H-desipramine was inhibited by tricyclic antidepressants and other noradrenaline uptake blockers. There was a highly significant correlation between the potencies of a series of drugs for the inhibition of³H-desipramine binding and for the inhibition of³H-noradrenanne uptake into intact PC-12 cells. Both, binding of³H-desipramine and uptake of³H-noradrenaline, were stereoselectively inhibited by the enantiomers of cocaine and oxaprotiline. However, for most of the substrates of uptake₁ the IC₅₀ for inhibition of³H-desipramine binding was much higher than that for inhibition of³H-noradrenaline uptake. Nevertheless, noradrenaline competitively inhibited³H-desipramine binding and unmasked dissociation of bound³H-desipramine. Thus,³H-desipramine probably binds to the substrate recognition site.From theB _max of³H-desipramine binding to PC-12 membranes and from theV _max of³H-noradrenaline uptake into PC-12 cells, a duration of about 400 ms for the transport cycle for a single noradrenaline molecule was calculated. In addition, from theB _max the maximum number of³H-desipramine binding sites (carriers) for a single PC-12 cell was calculated to be 55,000.A part of this study was presented at the IUPAHR 9th International Congress of Pharmacology (Bönisch et al. 1984)This study was supported by the Deutsche Forschungsgemeinschaft (Bo 521 and SFB 176)